Current partner codePEPTIDESDE
NCT06956365·Not applicable·INTERVENTIONAL

To Compare the Effects of Oxytocin and Carbetocin on Intraoperative Hemodynamic Changes in Cesarean Section Surgeries.

Status

Recruiting

Phase

Not applicable

Enrollment

80

Locations

1

Results

Not posted

Publications

3

Study summary

What the protocol is testing.

To compare the effects of oxytocin and carbetocin, used as uterotonics in elective caesarean section surgeries, in terms of intraoperative hemodynamic changes.

Full detailed description

The study will have a double-blind design and will be conducted after obtaining an approval from the local ethics committee. The study will include 80 patients planned for elective caesarean section surgeries , aged 18-40 years with an ASA score of I-II. The patients will be randomized by sealed tender and will be divided into 2 groups with 40 patients each. All cases will receive routine preparation for general anesthesia. All patients placed on the operating room will receive two large-bore vascular access. For anesthesia induction 2 mg/kg propofol and 0.5 mg/kg rocuronium will be used. Anesthesia will be maintained with 60% air, 40% oxygen and 2 MAC sevoflurane.Demographic data of the patients (age, height, weight), ASA score and surgical time will be recorded. During the operation, hemodynamic parameters will be recorded just before the drugs are given and at the 1st, 5th, 10th, 15th, 20th, 25th and 30th minutes after the drug is given. In addition, intraoperative blood loss and the need for additional uterotonics throughout the surgery will be recorded. All data will be recorded and statistical analysis will be made.

Interventions

Treatment arms and agents.

PROCEDURE

Group-C

100 iu carbetosin administered to carbetocin group

PROCEDURE

Group-O

In cesarean surgery, 5 IU of oxytocin will be administered after the baby delivered.

Timeline

From registration to results.

  1. First posted

    May 4, 2025

  2. Study start

    May 14, 2024

  3. Primary completion

    May 30, 2025

  4. Study completion

    Jul 30, 2025

  5. Results posted

    Not reported

  6. Registry updated

    May 4, 2025

Outcomes

What the study measures.

Primary outcomes

Uterine tonus

Time frame · For 30 minutes after carbetocin administration.

The effect of carbetocin on uterine tone will be evaluated by the surgical team using a numerical scoring scale between 0-10. A score of 0 will indicate atony, and a score of 10 will indicate full contraction.

Additional uterotonic drug requirement

Time frame · For 30 minutes after carbetocin administration.

If the uterine tone is 7 or below, the surgical team will perform uterine massage, and in patients who do not see a sufficient increase in uterine tone, an additional uterotonic, 0.2 mg methylergonavine (Methyl ampoule 0.2 mg/ml) will be administered IM by the anesthesia team and recorded.

Secondary outcomes

Intraoperative bleeding

Time frame · from drug administration to the end of surgery.

Total intraoperative bleeding was recorded by calculating and estimating the aspirator volume, pad-sponge-compress count and surgical area.

Mean Blood Pressure

Time frame · Intraoperatively every 5 minutes

Mean blood pressure will be measured every 5 minutes intraoperatively using a noninvasive method.

Heart Rate

Time frame · Intraoperatively every 5 minutes

Heart rate will be measured every 5 minutes intraoperatively using a noninvasive method.

Eligibility

Who can take part.

Minimum age
18 Years
Maximum age
40 Years
Sex
FEMALE
Healthy volunteers
Yes

Inclusion Criteria: * Patients scheduled for caesarean sections * Between 18-40 years * ASA I-II group * Those who will undergo general anesthesia * Those between 35-40 weeks of pregnancy * 1st and 2nd caesarean sections Exclusion Criteria: * Those who prefer spinal or epidural anesthesia * Those who are outside the age range of 18-40 * Those who are ASA III and above * Those with HT, DM, cardiac and respiratory diseases * Preeclampsia, eclampsia, HELLP * Those with a history of drug use that affects the cardiovascular system * Placenta Previa, Placenta Acreta, Placenta Acreta

Study locations

1 registered sites.

Turkey (Türkiye). Showing up to 24 locations stored in the fast local snapshot.

Van Yuzuncu Yil University

Van, Tuşba, Turkey (Türkiye)

Related trials

More studies on Carbetocin.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.